title: Latanoprost for uncontrolled glaucoma in a compassionate case protocol.
abstract: OBJECTIVE
  To evaluate the ocular hypotensive response of latanoprost 0.005% administered as adjunctive therapy in patients with glaucoma who were receiving maximal tolerated medical therapy.
  
  
  METHODS
  Consecutive patients entering a latanoprost compassionate clinical trial were enrolled at two sites. Latanoprost 0.005% was administered as a single drop between 6 and 8 PM, and all other medications were continued. Intraocular pressure was measured between 2 and 4 PM. Responders were defined as having a reduction in intraocular pressure of at least 20% from baseline.
  
  
  RESULTS
  In 160 eyes of 160 patients, mean baseline intraocular pressure +/- SD was 23.3 +/- 6.9 mm Hg. Intraocular pressure was significantly reduced compared with baseline measurements (P < .01) with mean intraocular pressure measurement reductions of 4.1 +/- 5.2, 4.0 +/- 6.3, and 3.7 +/- 4.2 mm Hg at the 1-, 3-, and 6-month intervals, respectively. A reduction in intraocular pressure of at least 20% was observed in 64 (44.4%) of 144 patients, 46 (43.0%) of 107 patients, and 10 (32.3%) of 31 patients at the 1-, 3-, and 6-month visits, respectively. A 40% reduction in intraocular pressure was observed in 18 (12.5%) of 144 and nine (8.4%) of 107 patients at 1 and 3 months, respectively. Mean reduction in intraocular pressure was similar in the miotic and nonmiotic groups (P > .4 at all intervals). Eight patients (5.0%) developed ocular allergy or irritation necessitating cessation of latanoprost therapy.
  
  
  CONCLUSIONS
  Latanoprost 0.005% may provide significant further intraocular pressure reduction in patients already receiving maximal tolerated medical therapy.
authors.affiliation: Department of Ophthalmology, New York Eye and Ear Infirmary, New York 10003, USA.
authors.forename: B
authors.initials: B
authors.lastname: Patelska
authors.forename: D S
authors.initials: DS
authors.lastname: Greenfield
authors.forename: J M
authors.initials: JM
authors.lastname: Liebmann
authors.forename: M
authors.initials: M
authors.lastname: Wand
authors.forename: H
authors.initials: H
authors.lastname: Kushnick
authors.forename: R
authors.initials: R
authors.lastname: Ritch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017024:Chemotherapy, Adjuvant; D002648:Child; D002985:Clinical Protocols; D004342:Drug Hypersensitivity / Q000209:etiology; D004357:Drug Synergism; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost